Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milo Gatti

Showing results (61-70 of 168) with videos related to

Pageof 17
Sort By:
Journal of Global Antimicrobial Resistance|June 3, 2023
Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection due to OXA-181-producing Klebsiella pneumoniaeMilo Gatti, Matteo Rinaldi, Paolo Gaibani, et al.
Microorganisms|January 23, 2024
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin-Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing <i>Enterobacterales</i> Secondary Bloodstream Infections: Findings from a Prospective Pilot StudyMilo Gatti, Cecilia Bonazzetti, Renato Pascale, et al.
Antibiotics (Basel, Switzerland)|December 23, 2022
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infections and/or Hospital-Acquired PneumoniaMilo Gatti, Maddalena Giannella, Matteo Rinaldi, et al.
Antibiotics (Basel, Switzerland)|December 23, 2023
Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing <i>Enterobacterales</i> Bloodstream Infections and/or Ventilator-Associated Pneumonia?Milo Gatti, Matteo Rinaldi, Tommaso Tonetti, et al.
International Journal of Antimicrobial Agents|February 7, 2024
Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatmentStefano Amadesi, Milo Gatti, Matteo Rinaldi, et al.
European Journal of Preventive Cardiology|August 17, 2021
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting systemMilo Gatti, Ippazio Cosimo Antonazzo, Igor Diemberger, et al.
Antibiotics (Basel, Switzerland)|April 26, 2024
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAPMilo Gatti, Matteo Rinaldi, Tommaso Tonetti, et al.
Antibiotics (Basel, Switzerland)|November 24, 2023
Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative InfectionsMilo Gatti, Matteo Rinaldi, Cristiana Laici, et al.
Antibiotics (Basel, Switzerland)|October 27, 2023
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous HemodiafiltrationMilo Gatti, Matteo Rinaldi, Tommaso Tonetti, et al.
Antibiotics (Basel, Switzerland)|December 23, 2023
In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing <i>Klebsiella pneumoniae</i> Clinical IsolatesMarta Palombo, Benedetta Secci, Federica Bovo, et al.
Pageof 17

Showing results (61-70 of 168) with videos related to

Sort By:
Pageof 17
Journal of Global Antimicrobial Resistance|June 3, 2023
Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection due to OXA-181-producing Klebsiella pneumoniaeMilo Gatti, Matteo Rinaldi, Paolo Gaibani, et al.
Microorganisms|January 23, 2024
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin-Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing <i>Enterobacterales</i> Secondary Bloodstream Infections: Findings from a Prospective Pilot StudyMilo Gatti, Cecilia Bonazzetti, Renato Pascale, et al.
Antibiotics (Basel, Switzerland)|December 23, 2022
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infections and/or Hospital-Acquired PneumoniaMilo Gatti, Maddalena Giannella, Matteo Rinaldi, et al.
Antibiotics (Basel, Switzerland)|December 23, 2023
Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing <i>Enterobacterales</i> Bloodstream Infections and/or Ventilator-Associated Pneumonia?Milo Gatti, Matteo Rinaldi, Tommaso Tonetti, et al.
International Journal of Antimicrobial Agents|February 7, 2024
Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatmentStefano Amadesi, Milo Gatti, Matteo Rinaldi, et al.
European Journal of Preventive Cardiology|August 17, 2021
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting systemMilo Gatti, Ippazio Cosimo Antonazzo, Igor Diemberger, et al.
Antibiotics (Basel, Switzerland)|April 26, 2024
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAPMilo Gatti, Matteo Rinaldi, Tommaso Tonetti, et al.
Antibiotics (Basel, Switzerland)|November 24, 2023
Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative InfectionsMilo Gatti, Matteo Rinaldi, Cristiana Laici, et al.
Antibiotics (Basel, Switzerland)|October 27, 2023
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous HemodiafiltrationMilo Gatti, Matteo Rinaldi, Tommaso Tonetti, et al.
Antibiotics (Basel, Switzerland)|December 23, 2023
In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing <i>Klebsiella pneumoniae</i> Clinical IsolatesMarta Palombo, Benedetta Secci, Federica Bovo, et al.
Pageof 17